Collectionner le produit
Détails du produit
Synonym
CD4, CD4mut, LEU3
Source
APC-Labeled Human CD4 Protein, His Tag (CD4-HA2H9) is produced via conjugation of APC to Human CD4 Protein, His Tag with a new generation site-specific technology under Star Staining labeling platform. Human CD4 Protein, His Tag is expressed from human 293 cells (HEK293). It contains AA Lys 26 - Pro 396 (Accession # AAH25782).
Predicted N-terminus: Lys 26
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus.
Conjugate
APC
Excitation Wavelength: 640 nm
Emission Wavelength: 661 nm
Purity
>90% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, 0.2% BSA, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please protect from light and avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Les clients ont également consulté
Affichage des données
Evaluation of CAR expression
FACS Analysis of Anti-CD4 CAR Expression
5e5 of anti-CD4 (Ibalizumab) CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of APC-Labeled Human CD4 Protein, His Tag (Cat. No. CD4-HA2H9) and negative control protein respectively (Fig. C and B), and non-transfected 293 cells were used as a control (Fig. A). APC signal was used to evaluate the binding activity (QC tested).
ProtocolFACS Analysis of Non-specific binding to PBMCs
5e5 of PBMCs were stained with APC-Labeled Human CD4 Protein, His Tag (Cat. No. CD4-HA2H9) and anti-CD3 antibody, washed and then analyzed with FACS. FITC signal was used to evaluate the expression of CD3+ T cells in PBMCs, and APC signal was used to evaluate the non-specific binding activity to PBMCs (QC tested).
Protocol
Avis des utilisateurs Publier un commentaire
Introduction de fond
Progrès de frontière
Progrès du développement médicamenteux- Nom anglais：
T-cell surface antigen CD4
- Catégorie：
- Nombre de médicaments répertoriés：
1 Détails
- Nombre de médicaments cliniques：
25 Détails
- Étape de développement la plus élevée：
Approved
Contact Us
Drug Candidate Licensing
